EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S J Robinson iD

British Journal of Pharmacology · 2026-07 · 183 (14) · 3970-3991

DOI: 10.1111/bph.17370 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2024-10-28. Written by Laith Alexander and 5 co-authors. Institution: Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Major MEDLINE topics: Hallucinogens, Major Depressive Disorder, Antidepressive Agents. Cited 11 times so far (Crossref); 210 references. The full text is freely available (open access, CC BY 4.0). Funded by: Biotechnology and Biological Sciences Research Council, National Institute for Health Research (NIHR) Biomedical Research Centre, National Institute for Health Research (NIHR).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood. For example, key questions such as whether antidepressant and psychedelic effects involve related or independent mechanisms are unresolved. Preclinical studies in relevant animal models are key to understanding the pharmacology of psychedelics and translating these findings to explain efficacy and safety in patients. Understanding the mechanisms of action associated with the behavioural effects of psychedelic drugs can also support the identification of novel drug targets and more effective treatments. Here we review the behavioural approaches currently used to quantify the psychedelic and antidepressant effects of psychedelic drugs. We discuss conceptual and methodological issues, the importance of using clinically relevant doses and the need to consider possible sex differences in preclinical psychedelic studies. LINKED ARTICLES This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc

Subjects

MeSH terms (MEDLINE)

HallucinogensMajor Depressive DisorderAntidepressive AgentsAnimalsHumansDrug Evaluation, PreclinicalDisease Models, AnimalBehavior, Animal

Author keywords

antidepressantbehaviourhallucinogenicneuropsychologytranslation

Substances

HallucinogensAntidepressive Agents

Authors and institutions

  • Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • South London and the Maudsley NHS Foundation Trust, London, UK.
  • School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol, UK.

ORCID profiles: Emma S J Robinson

Funding

  • Biotechnology and Biological Sciences Research Council
  • National Institute for Health Research (NIHR) Biomedical Research Centre
  • National Institute for Health Research (NIHR)
  • Wellcome Trust
  • NIHR Academic Clinical Fellowship
  • National Institute for Health and Care Research
  • NIHR Cambridge Biomedical Research Centre

Cite

APA

Alexander, L., Anderson, D., Baxter, L., Claydon, M., Rucker, J., & Robinson, E. S. J. (2026). Preclinical models for evaluating psychedelics in the treatment of major depressive disorder. British Journal of Pharmacology, 183(14), 3970-3991. https://doi.org/10.1111/bph.17370

Vancouver

Alexander L, Anderson D, Baxter L, Claydon M, Rucker J, Robinson ESJ. Preclinical models for evaluating psychedelics in the treatment of major depressive disorder. British Journal of Pharmacology. 2026;183(14):3970-3991. doi:10.1111/bph.17370

BibTeX
@article{Alexander2026,
  author = {Alexander, Laith and Anderson, Dasha and Baxter, Luke and Claydon, Matthew and Rucker, James and Robinson, Emma S J},
  title = {Preclinical models for evaluating psychedelics in the treatment of major depressive disorder},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {14},
  pages = {3970--3991},
  doi = {10.1111/bph.17370}
}
Start for free →